Status:
COMPLETED
Alternate Day Buprenorphine Administration, Phase X - 15
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborating Sponsors:
University of Vermont
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
34-51 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine how subjects will make changes in the amount of medication received when given a monetary alternative to buprenorphine.
Eligibility Criteria
Please contact site for information.
Key Trial Info
Start Date :
May 1 1993
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000233
Start Date
May 1 1993
Last Update
August 17 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Treatment Research Center
Burlington, Vermont, United States, 05401